Arbutus Biopharma Business Summary

Arbutus Biopharma Corp (ABUS) is a clinical-stage biopharmaceutical company dedicated to developing a functional cure for chronic hepatitis B virus (HBV) through a multi-pronged therapeutic approach. The company generates revenue primarily through strategic licensing agreements, such as its partnership with Alnylam Pharmaceuticals, and the monetization of its proprietary Lipid Nanoparticle (LNP) delivery technology. Its primary business segments are centered on its clinical pipeline, led by imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 checkpoint inhibitor. Additionally, Arbutus maintains a significant intellectual property position in LNP technology, currently the subject of high-stakes patent litigation against Moderna regarding COVID-19 vaccine applications, which represents a potential source of future royalty or settlement income. Direct competitors include GSK, Vir Biotechnology, Gilead Sciences, and Brii Biosciences; Arbutus distinguishes itself by focusing on combination regimens designed to achieve HBsAg loss and immune restoration, positioning it as a specialized innovator in the race for a finite-duration HBV cure. Arbutus was formed through the 2015 merger of Tekmira Pharmaceuticals and OnCore Biopharma, a transaction spearheaded by Vivek Ramaswamy and OnCore co-founders Michael J. Sofia and Patrick T. Higgins. As of February 2026, the company is led by President and CEO Lindsay Androski, an MIT-trained biologist and JD/MBA with nearly 30 years of experience in biotechnology and law, previously serving as special counsel at Genevant Sciences and a senior executive at Roivant. The executive team includes CFO Tuan Nguyen, a strategic finance veteran formerly of Kinevant Sciences, and General Counsel Andrew J. Sung. The company maintains strong institutional backing, notably from Morgan Stanley, which holds a 13.5% stake, and Roivant Sciences. The Board of Directors features prominent industry figures including Roivant CEO Matthew Gline and Dr. Roger Sawhney, reflecting a leadership pedigree deeply rooted in high-value biopharma acquisitions and clinical development scaling.